Objective To investigate the efficacy of sodium-dependent glucose transporters 2 inhibitor (SGLT-2i) Empagliflozin in the treatment of type 2 diabetes mellitus (T2DM)in a management mode of the internet plus mobile medicine. Methods From January 2017 to December 2019, a total of 97 T2DM patients with poorly controlled blood glucose in the Outpatient of Endocrinology Department of Chinese PLA General Hospital were randomly divided into the care group (n = 49) and the control group (n = 48). The patients were treated with Empagliflozin in addition to the basic hypoglycemic regimen. The care group were managed in a mode of the internet plus mobile medicine, and the control group in the routine outpatient clinics. After 6 months, the two groups were compared in the clinical indexes, self-management abilities featuring diet control, medication compliance, blood glucose monitoring and smoking cessation qualified rate, and the scores of self-rating anxiety scale (SAS). SPSS statistics 16.0 was used for statistical analysis. Data comparison between two groups was performed using t test or χ² test depending on data type. Results After management, the care group and control group differed in fasting blood glucose [ (6.2±0.3) vs (7.9±0.4) mmol/L], 2 h postprandial blood glucose [(9.5±0.5) vs (10.7±0.7) mmol/L], hemoglobin A1c [(7.0±0.3) vs (7.9±0.7)%], triglyceride [(1.41±0.57) vs (2.09±0.62) mmol/L], urine albumin/creatinine [(14.4±8.4) vs (19.3±10.5) mg/mmol], and body mass index [(24.2±2.7) vs (25.7±2.5) kg/m²] (P<0.05 for all). The care group had higher qualified rates of diet control [38(77.6%) vs 12(25%)], medication compliance [47(95.9%) vs 36(75%)], blood glucose monitoring [44(89.8%) vs 31(64.6%)], and smoking cessation [39(79.6%) vs 29(60.4%)] than the control group, and the differences were statistically significant (P<0.05). The SAS scores between two groups was statistically significant(P<0.05). Conclusion The mode of internet plus mobile medicine can improve the clinical indicators of T2DM patients who take orally Empagliflozin, reduce anxiety scores, and enhance the patient′s self-management. It is suitable for long-term management of chronic diseases.